New strategies for the treatment of metastatic bone disease Report uri icon

Overview

MeSH Major

  • Desensitization, Immunologic
  • HLA Antigens
  • Hematopoietic Stem Cell Transplantation
  • Leukemia, Myeloid, Acute

abstract

  • The introduction of bisphosphonates represents an important advance in the care of patients with metastatic bone disease. Nonetheless, we remain unable to prevent metastatic bone destruction. This review will discuss several novel therapies, including inhibitors of receptor activator of nuclear factor-kappabeta, c-Src, mammalian target of rapamycin, cathepsin K, and alpha(5)beta(3) integrins, which could improve our control over this devastating complication.

publication date

  • January 2007

Research

keywords

  • Report

Identity

Digital Object Identifier (DOI)

  • 10.3816/CBC.2007.s.010

Additional Document Info

start page

  • S35

end page

  • 45

volume

  • 8

number

  • SUPPL. 1